Clinical Trial Update: Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intratumoral Hiltonol (poly-ICLC) for solid tumors was terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Cancer of the Skin
• Breast Cancer
• Melanoma
• Sarcoma of the Skin
• Squamous Cell Carcinoma of the Head and Neck
• Squamous Cell Carcinoma of the Skin

Drugs mentioned

• Hiltonol (Poly-ICLC)

Snippet

Sponsor: Nina Bhardwaj | Conditions: Melanoma, Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Status: TERMINATED | Results posted: 2018-01-23